Jump to ContentJump to Main Navigation
Show Summary Details
Weitere Optionen …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Hrsg. v. Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
Alle Formate und Preise
Weitere Optionen …
Band 51, Heft 9

Hefte

Thiosulfate in urine as a facilitator in the diagnosis of prostate cancer for patients with prostate-specific antigen less or equal 10 ng/mL

Grażyna Chwatko / Ewa Forma / Jacek Wilkosz / Rafał Głowacki / Paweł Jóźwiak / Waldemar Różański / Magdalena Bryś / Anna Krześlak
Online erschienen: 06.07.2013 | DOI: https://doi.org/10.1515/cclm-2013-0069

Abstract

Background: The aim of this study was to examine the level of thiosulfate in the urine of prostate cancer (PCa) patients and evaluate its usefulness in the diagnosis and monitoring of prostate malignant transformation. Thiosulfate is a naturally occurring product of hydrogen sulfide (H2S) metabolism. H2S is involved in many physiological and pathological processes including inflammation and tumorigenesis.

Methods: The determination of thiosulfate in the urine of PCa patients and healthy controls was performed by reverse-phased liquid chromatography using 2-chloro-1-methylquinolinium tetrafluoroborate as a derivatization reagent. Thiosulfate concentrations were normalized to urinary creatinine levels to compensate for variable diuresis.

Results: In the urine samples of PCa patients, the mean thiosulfate level was almost 50 times higher than in the control groups and five times higher than in the benign prostatic hyperplasia group. The level of thiosulfate did not correlate with the serum prostate-specific antigen (PSA) level or PSA density. Neither tumor stage nor tumor grade was associated with thiosulfate level.

Conclusions: The results suggest that thiosulfate concentration in urine may be a good facilitator in the diagnostics of PCa. The predictive accuracy of this method is particularly valuable for the diagnosis of patients with low serum PSA level and negative digital rectal examination and transrectal ultrasound results.

Keywords: high-performance liquid chromatography (HPLC); prostate cancer; prostate-specific antigen (PSA); thiosulfate

References

  • 1.

    Roobol MJ, Haese A, Bjartell A. Tumour markers in prostate cancer III: biomarkers in urine. Acta Oncol 2011;50(Suppl 1):85–9.Web of SciencePubMedGoogle Scholar

  • 2.

    Strope SA, Andriole GL. Prostate cancer screening: current status and future perspectives. Nat Rev Urol 2010;7:487–93.Web of ScienceGoogle Scholar

  • 3.

    Berretta R, Moscato P. Cancer biomarker discovery: the entropic hallmark. PLoS One 2010;18:e12262.Web of ScienceCrossrefGoogle Scholar

  • 4.

    Couzin J. Biomarkers. Metabolite in urine may point to high-risk prostate cancer. Science 2009;323:865.Google Scholar

  • 5.

    Durand M, Weinstein P. Thiosulfate in human urine following minor exposure to hydrogen sulfide: implications for forensic analysis of poisoning. Forensic Toxicol 2007;25:92–5.Google Scholar

  • 6.

    Kage S, Takekawa K, Kurosaki K, Imamura T, Kudo K. The usefulness of thiosulfate as an indicator of hydrogen sulfide poisoning: three cases. Int J Legal Med 1997;110:220–2.Google Scholar

  • 7.

    Lavu M, Bhushan S, Lefer, DJ. Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential. Clin Sci 2010;120:219–29.Web of ScienceGoogle Scholar

  • 8.

    Whiteman M, Moore PK. Hydrogen sulfide and the vasculature: a novel vasculoprotective entity and regulator of nitric oxide bioavailability? J Cell Mol Med 2009;13:488–507.Web of ScienceGoogle Scholar

  • 9.

    Whiteman M, Winyard PG. Hydrogen sulfide and inflammation: the good, the bad, the ugly and the promising. Expert Rev Clin Pharmacol 2011;4:13–32.Google Scholar

  • 10.

    Gong QH, Shi XR, Hong ZY, Pan LL, Liu XH, Zhu YZ. A new hope for neurodegeneration: possible role of hydrogen sulfide. J Alzheimers Dis 2011;24:173–82.Web of ScienceGoogle Scholar

  • 11.

    Whiteman M, Gooding KM, Whatmore JL, Ball CI, Mawson D, Skinner K, et al. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulphide. Diabetologia 2010;53:1722–6.Web of ScienceGoogle Scholar

  • 12.

    Cole DE, Evrovski J. Screening for sulfite oxidase deficiency with urinary thiosulfate/sulfate ratios determined by anion chromatography. Clin Chem 1996;42:654–5.Google Scholar

  • 13.

    Belardinelli MC, Chabli A, Chadefaux-Vekemans B, Kamoun P. Urinary sulfur compounds in Down syndrome. Clin Chem 2001;47:1500–1.Google Scholar

  • 14.

    Torun M, Bayhan A, Yentür G. Response of allergic and normal persons to sulfiting agents in wine: determination of thiosulfate excretion in urine. Clin Chem 1989;35:1792–3.Google Scholar

  • 15.

    Baskar R, Bian J. Hydrogen sulfide gas has cell growth regulatory role. Eur J Pharmacol 2011;656:5–9.Google Scholar

  • 16.

    Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008;179:1587–92.Google Scholar

  • 17.

    Chwatko G, Bald E. Determination of thiosulfate in human urine by high performance liquid chromatography. Talanta 2009;79:229–34.Google Scholar

  • 18.

    Shi H, Ma Y, Ma Y. A simple and fast method to determine and quantify urinary creatinine. Anal Chim Acta 1995;312:79–83.Google Scholar

  • 19.

    Jung K. Enzyme activities in urine: how should we express their excretion? A critical literature review. Eur J Clin Chem Clin Biochem 1991;29:725–9.Google Scholar

  • 20.

    Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910–4.Web of ScienceGoogle Scholar

  • 21.

    Cai WJ, Wang MJ, Ju LH, Wang C, Zhu YC. Hydrogen sulfide induces human colon cancer cell proliferation: role of Akt, ERK and p21. Cell Biol Int 2010;34:565–72.Web of ScienceGoogle Scholar

  • 22.

    Cao Q, Zhang L, Yang G, Xu C, Wang R. Butyrate-stimulated H2S production in colon cancer cells. Antioxi Redox Signal 2010;12:1101–9.Google Scholar

  • 23.

    Guo H, Gai JW, Wang Y, Jin HF, Du JB, Jin J. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells. Urology 2012;79:483.e1–5.Web of ScienceGoogle Scholar

  • 24.

    Łowicka E. Bełtowski J. Hydrogen sulfide (H2S) – the third gas of interest for pharmacologists. Pharmacol Rep 2007;59:4–24.Google Scholar

  • 25.

    Ramasamy S, Singh S, Taniere P, Langman MJ, Eggo MC. Sulfide-detoxifying enzymes in human colon are decreased in cancer and upregulated in differentiation. Am J Physiol Gastroinvest 2006;191:288–96.Google Scholar

  • 26.

    Lee F, Torp-Pedersen S, Littrup PJ, McLeary RD, McHugh TA, Smid AP, et al. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen. Radiology 1989;170:29–32.Google Scholar

  • 27.

    Crawford ED, Leewansangtong S, Goktas S, Holthaus K, Baier M. Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/mL and age-specific reference range as a cut-off for abnormal values. Prostate 1999;3841:296–302.Google Scholar

  • 28.

    Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardio PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994;151:1283–90.Google Scholar

  • 29.

    Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817–21.Google Scholar

  • 30.

    Ciatto S, Bonardi R, Mazzotta A, Lombardi C, Santoni R, Cardini S, et al. Comparing two modalities of screening for prostate cancer: digital rectal examination+transrectal ultrasonography vs. prostate-specific antigen. Tumori 1995;81:225–9.Google Scholar

  • 31.

    Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 2004;350:2239–46.Google Scholar

Artikelinformationen

Corresponding author: Grażyna Chwatko, Department of Environmental Chemistry, University of Łódź, 163 Pomorska Łódź, 90-236 Łódź, Poland, Phone: +48-42-6355841, Fax: +48-42-6355832


Erhalten: 25.01.2013

Angenommen: 17.06.2013

Online erschienen: 06.07.2013

Erschienen im Druck: 01.09.2013


Quellenangabe: Clinical Chemistry and Laboratory Medicine, Band 51, Heft 9, Seiten 1825–1831, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2013-0069.

Zitat exportieren

©2013 by Walter de Gruyter Berlin Boston.Get Permission

Zitierende Artikel

Hier finden Sie eine Übersicht über alle Crossref-gelisteten Publikationen, in denen dieser Artikel zitiert wird. Um automatisch über neue Zitierungen dieses Artikels informiert zu werden, aktivieren Sie einfach oben auf dieser Seite den „E-Mail-Alert: Neu zitiert“.

[1]
Joanna Czapla-Masztafiak, Krzysztof Okoń, Marek Gałka, Thomas Huthwelker, and Wojciech M. Kwiatek
Applied Spectroscopy, 2016, Jahrgang 70, Nummer 2, Seite 264
[2]
Joshua Corbin and Maria Ruiz-Echevarría
International Journal of Molecular Sciences, 2016, Jahrgang 17, Nummer 8, Seite 1208
[3]
Mingzhe Liu, Lingyun Wu, Sabine Montaut, and Guangdong Yang
Prostate Cancer, 2016, Jahrgang 2016, Seite 1
[4]
Carsten Stephan, Klaus Jung, and Bernhard Ralla
Future Oncology, 2015, Jahrgang 11, Nummer 20, Seite 2743
[5]
Dongdong Wu, Weirong Si, Mingjie Wang, Shuangyu Lv, Ailing Ji, and Yanzhang Li
Nitric Oxide, 2015, Jahrgang 50, Seite 38
[6]
[7]
Mark R. Hellmich, Ciro Coletta, Celia Chao, and Csaba Szabo
Antioxidants & Redox Signaling, 2015, Jahrgang 22, Nummer 5, Seite 424
[8]
Katalin Módis, Ciro Coletta, Antonia Asimakopoulou, Bartosz Szczesny, Celia Chao, Andreas Papapetropoulos, Mark R. Hellmich, and Csaba Szabo
Nitric Oxide, 2014, Jahrgang 41, Seite 146
[9]
Scott M. Wendroth, Tiffany N. Heady, Doris M. Haverstick, Lorin M. Bachmann, Mitchell G. Scott, James C. Boyd, and David E. Bruns
Clinica Chimica Acta, 2014, Jahrgang 431, Seite 77

Kommentare (0)